Pharmacokinetic Study of Levocetirizine Oral Solution

Inclusion Criteria: * Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GSK Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures. * Japanese male between 20 and 55 years of age inclusive, at the time of signing the informed consent. * Non-smoker or ex-smoker having ceased smoking for at least 6 months. * Body weight =\> 50 kg and BMI within the range 18.5 - 25.0 kg/m2 at screening. * A signed and dated written informed consent is obtained from the subject. * Able to complete all study procedures and planned treatment periods. * ALT, alkaline phosphatase and bilirubin =\< 1.5xULN (isolated bilirubin \> 1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \< 35%). * Single QTcB \< 450 msec at screening. Exclusion Criteria: * The subject is positive for syphilis, Hepatitis B surface antigen, Hepatitis C antibody, HIV1/2 antibody, or HTLV-1 antibody at screening. * Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones). * The subject has a history of allergic rhinitis. * T…